کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2170484 1093380 2014 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Death receptor agonist therapies for cancer, which is the right TRAIL?
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی بیولوژی سلول
پیش نمایش صفحه اول مقاله
Death receptor agonist therapies for cancer, which is the right TRAIL?
چکیده انگلیسی

The activation of cell-surface death receptors represents an attractive therapeutic strategy to promote apoptosis of tumor cells. Several investigational therapeutics that target this extrinsic pathway, including recombinant human Apo2L/TRAIL and monoclonal agonist antibodies directed against death receptors-4 (DR4) or -5 (DR5), have been evaluated in the clinic. Although Phase 1/1b studies provided encouraging preliminary results, findings from randomized Phase 2 studies failed to demonstrate significant clinical benefit. This has raised multiple questions as to why pre-clinical data were not predictive of clinical response. Results from clinical studies and insight into why current agents have failed to yield robust responses are discussed. In addition, new strategies for the development of next generation death receptor agonists are reviewed.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytokine & Growth Factor Reviews - Volume 25, Issue 2, April 2014, Pages 185–193
نویسندگان
,